Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) announced a share buyback of 40,000 shares at a cost of HKD 1.236 million on October 31 [1] Group 1 - The company executed a buyback program, indicating a potential strategy to enhance shareholder value [1] - The total expenditure for the buyback was HKD 1.236 million, reflecting the company's commitment to returning capital to shareholders [1] - The number of shares repurchased was 40,000, which may influence the stock's liquidity and market perception [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) announced a share buyback program, indicating a strategic move to enhance shareholder value through repurchasing shares in the market [1] Summary by Categories Share Buyback Details - The company repurchased 40,000 shares on October 31, 2025, for a total transaction amount of approximately HKD 1,236,230, with an average price of about HKD 30.91 per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 515,000 shares at a total cost of approximately HKD 16,305,450 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 美麗田園醫療健康產業有限公司 呈交日期： 2025年10月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02373 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Beauty Farm Medical and Health Industry Inc. 美麗田園醫療健康產業有限公司 * （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2373） 自願公告 市場股份回購 本公告由美麗田園醫療健康產業有限公司（「本公司」，連同其附屬公司統稱「本集 團」）自願刊發。 本公司欣然公佈，本公司於2025年10月31日於市場購回40,000股本公司股份，總交 易金額約1,236,230港元，交易平均價約每股30.91港元。自2025年10月15日至本公 告日期止期間，本公司已購回共515,000股股份，總對價約16,305,450港元。 本公司董事（「董事」）會（「董事會」）認為，目前的股份成交價並不反映股份的內在價 值和本公司的實際業務前景。董事會相信，股份購回體現了管理層對企業長期價值 的堅定信心，有利於提升本集團資本市場價值及股東回報能力。 ...

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) demonstrates strong confidence in its future development as evidenced by non-executive director Yi Lin's purchase of 61,000 shares in the open market, representing approximately 0.03% of the company's total issued shares as of the announcement date [1] Group 1 - Yi Lin, a partner at Defu Capital with over 20 years of experience in investment and financial management, has shown commitment to the company's prospects through this share purchase [1] - The investment by Yi Lin, who joined the board in August as a representative of Defu Capital, highlights the confidence of quality long-term capital in the company's future development [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) announced a share buyback on October 30, 2025, spending HKD 927,200 to repurchase 30,000 shares at a price range of HKD 30.905 to HKD 30.74 per share [1] Summary by Category - **Company Actions** - The company executed a buyback of 30,000 shares at a total cost of HKD 927,200 [1] - The buyback price per share ranged from HKD 30.905 to HKD 30.74 [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) announced the repurchase of 30,000 shares on October 30, 2025, for a total transaction amount of approximately HKD 927,150, with an average transaction price of about HKD 30.91 per share [1] Summary by Category - **Share Repurchase Details** - The company repurchased 30,000 shares [1] - The total transaction amount was approximately HKD 927,150 [1] - The average price per share during the transaction was about HKD 30.91 [1]

Core Viewpoint - Meili Tianyuan Healthcare (02373) repurchased 30,000 shares on October 30, 2025, for a total transaction amount of approximately HKD 927,150, with an average price of about HKD 30.91 per share [1] Summary by Category - **Share Repurchase Details** - The company repurchased 30,000 shares [1] - Total transaction amount was approximately HKD 927,150 [1] - Average price per share was about HKD 30.91 [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) demonstrates strong confidence in its future development through share buybacks and insider purchases, indicating a belief that current share prices do not reflect the company's intrinsic value [1] Group 1: Insider Transactions - Non-executive director Ms. Yi Lin purchased a total of 61,000 shares in the open market using personal funds on October 24, 2025, reflecting a strong belief in the company's future prospects [1] Group 2: Share Buyback Activity - On October 30, 2025, the company repurchased 30,000 shares at a total transaction amount of approximately HKD 927,150, with an average price of about HKD 30.91 per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 475,000 shares for a total consideration of approximately HKD 15,069,220 [1] Group 3: Management's Perspective - The board believes that the current trading price of the shares does not reflect their intrinsic value and the actual business prospects of the company [1] - The board asserts that the share buyback reflects management's strong confidence in the long-term value of the enterprise, which is beneficial for enhancing the company's market value and shareholder return capabilities [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) demonstrates strong confidence in its future development through share buybacks and insider purchases, indicating a belief that current share prices do not reflect the company's intrinsic value [1] Group 1: Insider Transactions - Non-executive director Yi Lin purchased a total of 61,000 shares in the open market on October 24, 2025, using personal funds, reflecting a strong belief in the company's future prospects [1] Group 2: Share Buyback Activity - On October 30, 2025, the company repurchased 30,000 shares at a total cost of approximately 927,150 HKD, with an average price of about 30.91 HKD per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 475,000 shares for a total consideration of approximately 15,069,220 HKD [1] Group 3: Management's Perspective - The board believes that the current trading price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The board asserts that the share buyback reflects management's strong confidence in the long-term value of the enterprise and is beneficial for enhancing the company's market value and shareholder return capabilities [1]